Onconetix, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

25.42 k

Shareholding (Dec 2024)

FII

2.71%

Held by 6 FIIs

DII

96.55%

Held by 1 DIIs

Promoter

0.00%

What does Onconetix, Inc. do?

22-Jun-2025

Onconetix, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry. Financial metrics such as net sales and profit are not available, and it has a dividend yield of 0.00%.

Is Onconetix, Inc. overvalued or undervalued?

20-Sep-2025

As of August 29, 2024, Onconetix, Inc. is considered a risky investment due to its negative P/E ratio, unfavorable EV to EBITDA ratio, lack of a PEG ratio, and significant underperformance with a YTD return of -94.4% compared to the S&P 500's 12.22% gain.

Is Onconetix, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Onconetix, Inc. has shifted to a mildly bearish trend, influenced by bearish daily moving averages and Bollinger Bands, despite a mildly bullish MACD, with a year-to-date return of -94.4% compared to the S&P 500's 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Negative results in Jun 25

NET SALES(HY) At USD 0.21 MM has Grown at -85.19%
DEBT-EQUITY RATIO (HY) Highest at 133.31 %

Risky - No result in last 6 months

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.33

Return on Equity

-999,999.00%

Price to Book

0.65

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.37%

6 Months

-56.41%

1 Year

-95.19%

2 Years

-99.72%

3 Years

104.37%

4 Years

0.0%

5 Years

0.0%

Onconetix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Onconetix, Inc. Hits New 52-Week Low at $2.45 Amid Major Decline

Onconetix, Inc., a microcap pharmaceutical company, recently hit a 52-week low, reflecting a significant decline in performance over the past year. With a market capitalization of around USD 4 million, the company faces challenges, including a low price-to-book ratio and a concerning debt-to-equity ratio, raising questions about its financial stability.

Is Onconetix, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Onconetix, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Bollinger Bands also showing a bearish signal. While the MACD remains mildly bullish on both weekly and monthly time frames, the overall trend is tempered by the bearish signals from the moving averages and Bollinger Bands. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -94.4% versus the S&P's 12.22%....

Is Onconetix, Inc. overvalued or undervalued?

As of 29 August 2024, the valuation grade for Onconetix, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative P/E ratio of -0.4976 and an EV to EBITDA ratio of -1.7044, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. Additionally, the lack of a PEG ratio indicates that growth expectations may not justify the current valuation. In comparison to peers, Onconetix, Inc. is underperforming, especially when contrasted with the broader industry metrics. For instance, while Onconetix has a negative P/E, other companies in the pharmaceuticals and biotechnology sector typically exhibit positive valuations. The recent stock performance further underscores this valuation concern, as Onconetix has seen a staggering YTD return of -94.4% compared to a 12....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

246.00%

EBIT Growth (5y)

48.80%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

5.40%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.74%)

Foreign Institutions

Held by 6 Foreign Institutions (2.71%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -85.71% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 83.22% vs -107.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.70",
          "chgp": "-85.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "-1.90",
          "chgp": "31.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.40",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-11.70",
          "chgp": "93.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-14.30",
          "chgp": "83.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,596.20%",
          "val2": "-3,003.30%",
          "chgp": "-959.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2,400.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -56.95% vs -179.10% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.50",
          "val2": "0.10",
          "chgp": "2,400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-15.80",
          "chgp": "53.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "0.70",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-50.40",
          "val2": "-20.90",
          "chgp": "-141.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.70",
          "val2": "-37.40",
          "chgp": "-56.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,221.40%",
          "val2": "-271,619.80%",
          "chgp": "26,839.84%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.10

0.70

-85.71%

Operating Profit (PBDIT) excl Other Income

-1.30

-1.90

31.58%

Interest

0.20

0.40

-50.00%

Exceptional Items

-0.80

-11.70

93.16%

Consolidate Net Profit

-2.40

-14.30

83.22%

Operating Profit Margin (Excl OI)

-12,596.20%

-3,003.30%

-959.29%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -85.71% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 83.22% vs -107.25% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.50

0.10

2,400.00%

Operating Profit (PBDIT) excl Other Income

-7.40

-15.80

53.16%

Interest

1.40

0.70

100.00%

Exceptional Items

-50.40

-20.90

-141.15%

Consolidate Net Profit

-58.70

-37.40

-56.95%

Operating Profit Margin (Excl OI)

-3,221.40%

-271,619.80%

26,839.84%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 2,400.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -56.95% vs -179.10% in Dec 2023

All Annual Results

Company CV

About Onconetix, Inc.

Onconetix, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Onconetix, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Onconetix, Inc. do?

Watch in Real-Time

Is Onconetix, Inc. overvalued or undervalued?

Is Onconetix, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Negative results in Jun 25

Risky - No result in last 6 months

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Onconetix, Inc. Hits New 52-Week Low at $2.45 Amid Major Decline

Is Onconetix, Inc. technically bullish or bearish?

Is Onconetix, Inc. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Onconetix, Inc.

Company Coordinates